Novo Holdings A/S's Form 4 filing
Metagenomi Therapeutics, Inc. (MGX) · filed Feb 15, 2024
- Accession no.
- 0001209191-24-003423
- Filed
- Feb 15, 2024
- Trade date
- Feb 9-13, 2024
- Filing delay
- 6 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $13.0M. It was filed 6 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Novo Holdings A/SCIK 0001388325 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2024 | COMMON STOCK | PPurchaseAcquired | +100,000 | $10.25 | +$1,025,000 | 100,000 | Direct | |
| Feb 13, 2024 | COMMON STOCK | CConversionAcquired | +839,175 | – | – | 939,175 | Direct | |
| Feb 13, 2024 | COMMON STOCK | PPurchaseAcquired | +800,000 | $15.00 | +$12,000,000 | 1,739,175 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 13, 2024 | COMMON STOCK | CConversionDisposed | −147,415 | – | – | 0 | Direct | |
| Feb 13, 2024 | COMMON STOCK | CConversionDisposed | −691,760 | – | – | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.